Small-cap ASX healthcare stocks offering potential buy opportunities

The healthcare sector is positioned for long-term growth driven by industry tailwinds and the following ASX companies which are operating with multiple upcoming catalysts that make them compelling investment opportunities.

Actinogen Medical Limited, Prescient Therapeutics Limited and Cleo Diagnostics Limited have strong growth potential based on recent performance and pipeline developments 

Actinogen Medical Limited (ASX: ACW)

on 18 December announced that the final 246th participant has been randomised and commenced treatment in its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial which confirms that topline results are now expected in November 2026.

The company received $5.5 million from the first tranche of its FY25 R&D tax incentive and expects a further $1.9 million rebate which lifts the pro forma cash position to approximately $12.4 million.

ACW is moving into a catalyst rich period with an interim analysis scheduled for January 2026 as the independent Data Monitoring Committee reviews unblinded data from completed participant visits alongside the commencement of the open label extension phase in Q1 2026.

ACW provides exposure to a differentiated oral Alzheimer’s therapy with late-stage clinical validation and multiple upcoming milestones which could improve investor sentiment.

Prescient Therapeutics Limited (ASX: PTX) 

on 15 December announced that the European Clinical Trials Information System has granted approval to commence its PTX-100 clinical trial in patients with relapsed or refractory Cutaneous T-cell Lymphoma in Italy. 
This authorisation will enable the company to activate clinical trial sites and begin patient recruitment for the Phase 2a study across Europe.

During the September 2025 quarter, the company successfully completed a $9.8 million capital raise and Prescient closed the September 2025 quarter with cash reserves of $12.32 million.

The proceeds from the placement are being used to advance the global Phase 2 clinical trial of PTX-100 in cutaneous T-cell lymphoma which is an area with limited effective treatment options 
For investors who are looking for huge potential upside driven by clinical trial progress, Prescient Therapeutics represents a compelling opportunity at this stage of its development journey

Cleo Diagnostics Limited (ASX: COV) 

on 18 December announced that it raised $5 million through a placement at $0.60 per share which will be used to support U.S. market entry, the commercial launch of the Pre-Surgical Ovarian Cancer Test and the development of a mass screening test.

The company also confirmed that it received a cash refund of $1.7 million from the Australian Government under the FY25 Research and Development (R&D) Tax Incentive scheme.

The company secured approximately 1,600 biobank samples which provide a high-quality internal dataset spanning multiple cancer stages including rare early-stage cases and this will support algorithm refinement and product development.

From a clinical perspective, recruitment for the pivotal U.S. trial continued to progress well with completion and sample analysis targeted for Q1 CY2026 which is a major catalyst for the company.
If execution continues as planned, the company is positioned to enter the large and underserved U.S. ovarian cancer diagnostics market in 2026 which could multiply its revenue profile.

(Source: Company Reports)